Form 4: Vaxcyte CEO Grant Pickering Sells Shares Under 10b5-1 Trading Plan

Vaxcyte's CEO, Grant Pickering, executed multiple sales of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Grant Pickering, CEO of Vaxcyte, Inc., sold shares of common stock on July 1, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on June 26, 2023.
• The transactions involved multiple sales at varying weighted-average prices.
• Some shares are held indirectly through trusts for the benefit of Pickering's children.
• A total of 2,616 shares were sold directly by Pickering at prices ranging from $75.43 to $77.155.
• Following the reported transactions, Pickering directly owns 478,888 shares.
• Pickering also indirectly owns 143,438 to 144,072 shares through children's trusts.

Sentiment

Score: 5

Explanation: The document is a routine SEC filing related to insider trading. The sentiment is neutral as it simply reports transactions.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Risks

• Executive share sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Insider transactions are common in the biopharmaceutical industry. Monitoring these transactions can provide insights into management's perspective on the company's valuation and prospects.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, but the existence of a 10b5-1 plan suggests it's part of a pre-determined strategy.

Key Dates